This podcast episode is part of a multimedia program discussing the co-management of moderate to severe atopic dermatitis (AD) in the primary care and specialty settings. Tune in to hear Dr Silverberg and NP Victoria Garcia-Albea highlight newly approved agents and the recent expanded labeling of an existing AD therapy, including: 

• Ruxolitinib, a topical JAK inhibitor for mild to moderate AD approved in 2021 
• Abrocitinib and upadacitinib, oral JAK inhibitors approved in early 2022 for moderate to severe AD
• Tralokinumab, an IL-13 inhibitor available as a subcutaneous injection, which was approved in late 2021 for moderate to severe AD
• Expanded approval for use in patients as young as 6 months for dupilumab, a subcutaneous IL-4 receptor α inhibitor

Presenters: 

Jonathan Silverberg, MD, PhD, MPH
Associate Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC

Victoria Garcia-Albea, PNP, DCNP, MSN, BSN, PRN
Director
Lahey Dermatology Nurse Practitioner Training Program
Lahey Hospital and Medical Center
Burlington, Massachusetts

To view other program offerings, including a CE-certified recorded roundtable webcast, a ClinicalThought commentary, and to download slides, visit:
https://bit.ly/3PiupXZ